Efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis

Shoji Yokobori1*, Tomoaki Yatabe2†, Yutaka Kondo3, Kosaku Kinoshita4 and for the Japan Resuscitation Council (JRC) Neuroresuscitation Task Force and the Guidelines Editorial Committee

Abstract

Background: The exacerbation of intracranial bleeding is critical in traumatic brain injury (TBI) patients. Tranexamic acid (TXA) has been used to improve outcomes in TBI patients. However, the effectiveness of TXA treatment remains unclear. This study aimed to assess the effect of administration of TXA on clinical outcomes in patients with TBI by systematically reviewing the literature and synthesizing evidence of randomized controlled trials (RCTs).

Methods: MEDLINE, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi (ICHUSHI) Web were searched. Selection criteria included randomized controlled trials with clinical outcomes of adult TBI patients administered TXA or placebo within 24 h after admission. Two investigators independently screened citations and conducted data extraction. The primary “critical” outcome was all-cause mortality. The secondary “important” outcomes were good neurological outcome rates, enlargement of bleeding, incidence of ischemia, and hemorrhagic intracranial complications. Random effect estimators with weights calculated by the inverse variance method were used to report risk ratios (RRs).

Results: A total of 640 records were screened. Seven studies were included for quantitative analysis. Of 10,044 patients from seven of the included studies, 5076 were randomly assigned to the TXA treatment group, and 4968 were assigned to placebo. In the TXA treatment group, 914 patients (18.0%) died, while 961 patients (19.3%) died in the placebo group. There was no significant difference between groups (RR, 0.93; 95% confidence interval, 0.86–1.01). No significant differences between the groups in other important outcomes were also observed.

(Continued on next page)
Conclusions: TXA treatment demonstrated a tendency to reduce head trauma-related deaths in the TBI population, with no significant incidence of thromboembolic events. TXA treatment may therefore be suggested in the initial TBI care.

Keywords: Clotting, TBI, Head-trauma, Hemorrhage, Fibrinolysis, Hematoma, Meta-analysis

Background

Traumatic brain injury (TBI) is a significant cause of mortality and morbidity worldwide, especially in children and young adults. In Japan, the main victims are elderly people, which exhibit slow recovery and therefore incur high medical costs [1]. TBI causes a high socioeconomic burden, incurring high medical expenses and loss of productivity [1, 2]. To reduce undesired outcomes of TBI, efforts to develop TBI treatment have been performed. However, the prognosis of TBI remains poor. In the USA, approximately 50,000 people die and at least 5.3 million live with disabilities related to TBI per year [3].

Recently, the pathophysiology of coagulopathy has been the focus of trauma care [4, 5]. Immediately after having TBI, the state of hyperfibrinolysis peaks within 3 h which causes hematoma expansion [6]. Thus, early (<1 h and no later than 3 h after injury) treatment with tranexamic acid (TXA), an anti-fibrinolysis drug, may be ideal for this trauma population [7, 8].

Several randomized controlled trials (RCTs) examining the efficacy of TXA in trauma patients have been performed in recent years [9–11]. However, an in-depth meta-analysis of the latest results of these larger RCTs is lacking. The aim of this study was thus to clarify the efficacy of acute TXA treatment in TBI patients by analyzing recent literatures.

Methods

We organized the systematic review team in the Japan Resuscitation Council (JRC) Neuroresuscitation Task Force. The JRC Neuroresuscitation Task Force and the Guidelines Editorial Committee was established in 2020 which organized by the Japan Society of Neuroemergencies and Critical Care, the Japanese Society of Intensive Care Medicine, and the Japan Society of Neurosurgical Emergency. The JRC Neuroresuscitation Task Force sets six clinically relevant questions, and this systematic review was performed.

We conducted a systematic review that conformed to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards [12]. This study was also registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry, which is the largest clinical trial registry in Japan (UMIN ID, 000040389).

With the discussion in this JRC Neuroresuscitation Task Force, population intervention comparator outcome study design and timeframe (PICOST) to guide a systematic review search was set as below.

P (patients): All types of adult TBIs.
I (interventions): Initial administration of TXA within 24 h after injury. Dose and method of administration of TXA were not limited.
C (comparisons, controls): Placebo or non-intervention.
O (outcomes): Primary, “critical” outcome as mortality from any cause and secondary, “important” outcomes as poor neurological outcomes (severe disability, vegetative state, and death in Glasgow Outcome Scale), ischemic or thromboembolic complications, and hemorrhagic complications.
S (study design): RCTs.
T (timeframe): All published literatures up to October 26, 2019.

We identified RCTs investigating the effects of TXA on mortality in TBI patients by searching PubMed, the Cochrane library, and Igaku Chuo Zasshi (ICHUSHI) Web up to October 26, 2019. ICHUSHI Web is the largest database of Japanese medical journals, containing approximately 10 million manuscripts from 6000 journals.

We included studies that fulfilled the following criteria: (1) an RCT, (2) a full-text publication in English or Japanese, (3) included adult patients with TBI, (4) included comparisons between TXA and placebo or non-intervention, and (5) initial administration of TXA within 24 h after injury. Dose and method of administration of TXA were not limited.

Two reviewers (TY and SY) independently abstracted the data and assessed the methodologic quality of the eligible studies. Two reviewers also achieved the consensus on this literature selection, and any disagreement between them over the eligibility of particular studies was resolved through discussion. Data abstracted from each study included the first author’s name, year of publication, number of study sites, number of patients, patient ages, proportion of females, duration between injury and administration of TXA, dose of TXA, and other treatment (surgery, transfusion, etc.). Methodologic quality was evaluated using the Cochrane risk of bias assessment tool [13], which assesses randomization; allocation...
concealment; blinding of study participants, personnel, and outcome assessments; incomplete outcome data; selective outcome reporting; and other potential sources of bias. The two reviewers achieved the consensus on the risk of bias (RoB), and any discrepancy of judge was resolved through discussion.

The grades of recommendation, assessment, development, and evaluation (GRADE) approach was also used to evaluate the certainty of the available evidence, like as inconsistency, indirectness, imprecision, and publication bias. We provided the evidence profile table using the GRADE pro GDT (GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from graderpro.org.). For the application of GRADE system, we received guidance from the Medical Information Network Distribution Service (MINDS), a Japanese center for GRADE education. Two reviewers also discussed the results of risk of bias and achieved the consensus on this final decision.

According to this GRADE approach, primary outcome was replaced as “critical,” and secondary outcomes were replaced as “important” outcomes [14].

We defined the critical outcome as hospital mortality and important outcomes as favorable neurological outcomes, progressive intracranial hemorrhage, and complications (thrombosis and bleeding). If hospital mortality data were not available, we substituted the 28 to 90-day mortality for hospital mortality. Poor neurological outcome was defined as severe disability (SD), persistent vegetable state (PVS), and dead (D) on Glasgow Coma Scale.

We performed the meta-analysis using Review Manager, version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Comparative odds ratios (ORs) were reported with their associated 95% confidence intervals (CIs). We selected a random effects model. Statistical heterogeneity was determined by assessing $I^2$ values, which were interpreted as follows: 0–40%, might not be important; 30–60%, may represent moderate heterogeneity; 50–90%, may represent substantial heterogeneity; and 75–100%, may represent considerable heterogeneity.

We conducted subgroup analyses to evaluate each outcome using only low risk of RoB RCTs. Therefore, we decided to create the evidence profile table based on this subgroup analyses before starting systematic review.

Results

Literature search strategy
A total of 800 studies were identified through database searching. After removing duplicated literature, 640 studies were eligible. Based on title and abstract assessment, 631 study records were excluded, and nine full text articles were included for full-text article assessment. After reading the full study literature, one study was excluded due to different patient populations, and one study was excluded due to study duplication. Thus, seven RCTs were finally included in this meta-analysis (Fig. 1). Searching formulae and the results of search are presented as Supplementary Table 1.

Characteristics
Characteristics of the included studies are summarized in Table 1. A total of 10,124 patients selected from seven RCTs [9, 15, 16, 18, 19] were randomly assigned to the TXA treatment group ($n = 5116$) versus placebo ($n = 5008$) for critical outcome analysis. Each study included 80 to 9127 patients, with ages ranging from 32 to 42 years. The proportion of women was 9 to 25%. The largest RCT population was in the CRASH-3 study, which was published in 2019 [9]. Two studies were multicenter.
RCTs. In all studies, initial dose of TXA was 1 g, and maintenance dose was 1 g.

Critical outcomes
Mortality from any cause was evaluated in six RCTs. Evidence profiles were shown as Supplementary Table 2. This set of six RCTs had less publication bias with the symmetric distribution in funnel plot (Supplementary Figure). With these RCTs analyzed, the forest plot of the critical outcomes is shown in Fig. 2. In this observation period, 914 patients (18.0%) died in the TXA-treated group, while 961 patients (19.3%) died in the placebo control group. There was a trend for superior critical outcomes in the TXA-treated group (RR, 0.93 [95% CI, 0.85–1.01]); however, this did not reach significance (P = 0.09, Fig. 2).

Important outcomes
The incidence of poor neurological outcomes was clarified in four RCTs [10, 15, 16, 18]. With this study population (n = 799), the forest plot for the detection of poor outcomes is shown in Fig. 3. Of 409 patients, 98 (23.9%) which received TXA exhibited poor outcomes, while 97 of 390 patients (24.9%) exhibited poor outcomes in the placebo control group. There was no significant difference in incidence of poor outcomes between TXA and placebo (RR, 0.90; 95% CI, [0.61–1.33]; P = 0.60).
Three RCTs [9, 15, 18] reported the incidence of ischemic complication, and only one RCT [9] reported hemorrhagic complication. With these patient cohorts (n = 9545 for ischemic complications and n = 9127 for hemorrhagic complications), sub-analyses did not reveal any significant differences (ischemic complication: RR, 1.33; 95% CI, [0.35–5.04]; P = 0.68; hemorrhagic complication: RR, 0.71; 95% CI, [0.37–1.35]; P = 0.30; Figs. 3, 4, and 5, respectively).

Subgroup analysis using low RoB RCTs

To assure the strong evidence on these critical and important outcomes, we chose low RoB RCSs to create the evidence profile table (Table 2). In this sub-analysis, four low RCTs are selected for the analysis of primary critical outcome, and there was a non-significant trend for superior in the TXA-treatment group (RR, 0.93 [95% CI, 0.85–1.01]), as same as primary analysis with 6 RCTs. Sub-analyses with low RoB relating on the three important outcomes also did not reveal any significant differences (poor neurological outcome: RR, 0.76 95% CI, [0.55–1.06]; ischemic complication: RR, 0.68; 95% CI, [0.12–3.93]; hemorrhagic complication: RR, 0.71; 95% CI, [0.37–1.35]) (Table 2).

Discussion

In this systematic review and meta-analysis, we aimed to clarify the efficacy of TXA administration compared to that of placebo in TBI patients. Several systematic reviews of TXA treatment in TBI patients have been published [20–22]. However, in these meta-analyses, the largest RCT, CRASH-3 Trial [9], was not included in the literature search. Our review is thus the first largest (n = 10,044) systematic review and meta-analysis of RCTs to compare TXA treatment and placebo. Our meta-analysis revealed that TXA administration showed a tendency to reduce head trauma-related death, but the results were not statistically significant.

TXA is an anti-fibrinolytic agent which has been used to treat or prevent excessive blood loss with many medical and surgical indications [23], including major trauma [8], postpartum bleeding [24], and orthopedic surgery [25]. TXA is a synthetic analog of the lysine, a kind of amino acid. This reduces conversion of plasminogen to plasmin, preventing fibrin degradation and preserving the framework of fibrin’s matrix structure. Thus, TXA serves as an antifibrinolytic agent. Indications for TXA treatment have been investigated clinically, targeting characteristic pathophysiology in TBI.

TBI is associated with coagulopathy, and the background of this pathophysiology has been reported in the recent literature [6, 26]. The pathophysiology of coagulopathy in TBI includes tissue factor activation,
thrombocytopenia, platelet dysfunction, protein C activation, and hyperfibrinolysis. The main mechanism of TBI-related coagulopathy is hyperfibrinolysis followed by primary consumptive coagulopathy that is caused by migration of tissue factors from injured brain tissue to blood. The peak of this hyperfibrinolysis occurs approximately 3 h after experiencing the injury [6]. Early treatment with TXA, an anti-fibrinolytic agent, is therefore considered reasonable.

Previous clinical research supports this hypothesis. The recent CRASH-2 trial, in which 20,211 trauma patients in 40 countries were enrolled, demonstrated the efficacy of TXA treatment for reducing bleeding in trauma patients [10] and reducing mortality in perinatal hemorrhagic patients [24].

Recently, CRASH-3 Trial, an RCT using TXA treatment for TBI, reported that TXA treatment was safe in patients with TBI. Among patients treated within 3 h of injury, the risk of head injury-related deaths was lower (18.5%) in the TXA group compared to 19.8% in the placebo (RR, 0.94; 95% CI, 0.86–1.02) in primary intention-to-treat analysis, but the superiority of TXA was not statistically significant [9]. Also, the risk of head injury-related death did not reduced with tranexamic acid in patients with severe head injury [9]. Thus, we aimed to establish this systematic review to clarify whether TXA treatment was effective for TBI patients by analyzing large patient cohorts.

CRASH-3 demonstrated that the risk of head injury-related deaths was reduced with TXA treatment in patients with mild-to-moderate head injury (RR, 0.78; 95% CI, 0.64–0.95) but not in patients with severe head injury (RR, 0.99; 95% CI, 0.91–1.07; p = 0.73), suggesting that TXA may be more effective in non-severe TBI patients. Further, CRASH-3 concluded that TXA treatment was more effective than later treatment in patients with mild and moderate head injury. It is necessary to understand the exact indication of TXA (i.e., severity and type of TBI) to determine which patients will benefit from TXA treatment.

Our results highlighted the safety and feasibility of TXA treatment with no significant difference in incidence of thromboembolic complications (1.7% in TXA versus 1.4% in placebo group; RR, 1.33; 95% CI, 0.35–5.04; p = 0.68). This result warrants the use of TXA for TBI, even in non-severe TBI. TXA is an inexpensive drug and is listed as an essential drug by the World Health Organization [27]. Even in developing countries, TXA treatment may be feasible in daily TBI care.

This meta-analysis has several limitations. First, only seven RCTs were included in our systematic review, with limited information on complications such as seizures [28]. Second, the severity and type of TBI were not mentioned in included RCTs. For example, the patient inclusion criteria of CRASH-3 were (1) Glasgow Coma Scale (GCS) score of 12 or lower and (2) intracranial bleeding on CT scan and no major extracranial bleeding. Thus, in the CRASH-3 trial, the pathophysiology of concussion or diffuse axonal injury was not completely ruled out. To titrate the indication of TXA for TBI, well-designed RCTs are needed in the future to support our findings.

Only one RCT (CRASH-3) mentioned hemorrhagic complications including hemorrhage worsening or progression. Further RCTs are required to form definite conclusions regarding the robustness/safety of this treatment.
| Certainty assessment                          | No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | TXA               | Placebo            | Effect              | Absolute (95% CI)   | Certainty | Importance |
|----------------------------------------------|----------------|--------------|--------------|---------------|--------------|-------------|---------------------|-------------------|--------------------|---------------------|---------------------|-----------|------------|
| Mortality from any cause (low RoB)           | 4              | Randomized   | Not serious  | Not serious   | Not serious  | None        |                     | 883/4940 (17.9%)  | 936/4844 (19.3%) | RR 0.93 (0.85 to 1.01) | 14 fewer per 1000 (from 29 fewer to 2 more) | High      | Critical   |
| Poor neurological outcome (low RoB)          | 3              | Randomized   | Not serious  | Not serious   | Not serious  | Serious*    | None                | 52/313 (16.6%)    | 67/306 (21.9%)    | RR 0.76 (0.55 to 1.06) | 53 fewer per 1000 (from 99 fewer to 13 more) | Moderate  | Critical   |
| Ischemic or thromboembolic complications (low RoB) | 2              | Randomized   | Not serious  | Very serious^c | Not serious  | None        |                     | 69/4733 (1.5%)    | 63/4632 (1.4%)    | RR 0.68 (0.12 to 3.99) | 4 fewer per 1000 (from 12 fewer to 40 more) | Very low  | Critical   |
| Hemorrhagic complications (bleeding, low RoB) | 1              | Randomized   | Not serious  | Not serious   | Very serious^c | None        |                     | 16/4613 (0.3%)    | 22/4514 (0.5%)    | RR 0.71 (0.37 to 1.35) | 1 fewer per 1000 (from 3 fewer to 2 more) | Low       | Critical   |

CI confidence interval, RR risk ratio, RoB risk of bias
Reasons of downgrade are as follows:
*Sample size is smaller than optimal information size. In addition, 95% CI is wide
^bI^2 value is high
^cSample size is smaller than optimal information size. In addition, 95% CI is very wide
Conclusions
Our meta-analysis demonstrated that TXA treatment showed a trend for reducing head trauma-related death in TBI patients, with no significant incidence of thromboembolic events. TXA treatment may therefore be suggested in the initial TBI care.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s40560-020-00460-5.

Additional file 1: Supplementary figure. Funnel plot of 6 randomized controlled trials. This set of six RCTs had less publication bias with the symmetric distribution.

Additional file 2: Supplementary Table 1. Evidence profile (including all RoB). Reasons of downgrade: a) Sample size is smaller than optimal information size. In addition, 95% CI is wide. b) I2 value is high. c) Sample size is smaller than optimal information size. In addition, 95% CI is very wide. CI: Confidence interval; RR: Risk ratio; RoB: Risk of Bias.

Abbreviations
TBI: Traumatic brain injury; TXA: Tranexamic acid; RR: Risk ratio; RCT: Randomized controlled trial

Acknowledgements
We would like to thank all the members of the JRC Neuroresuscitation Task Force collaborators (Yasuhiro Ajimi, Masaaki Iwase, Kyoko Umemoto, Junji Kumasawa, Jun Goto, Hitoshi Kobata, Atsushi Sawamura, Toru Hifumi, Eihei Hoshiyama, Mitsuru Honda, Yasuhiro Norisue, Shoji Matsumoto, Yasufumi Miyake, Takashi Moriya, Hitoyo Yasuda, Tornaki Yatabe, Kazuma Yamakawa, Sunghoon Yang, Masahiro Wakisugi, and Masao Nagayama). We also would like to thank Editage for English language editing.

Authors’ contributions
All authors were involved in the study design. SY and TY identified the studies entered in the meta-analysis and analyzed the data. SY drafted and TY supervised the manuscript. All authors were involved in data interpretation and discussion. All authors read and approved the final manuscript.

Funding
JRC and the Japan Society of Neuroemergencies and Critical Care (JNE), the Japanese Society of Intensive Care Medicine (JSICM), and the Japan Society of Neurosurgical Emergency as Member Societies of the JRC.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare no conflicts of interest.

Author details
1Department of Emergency and Critical Care Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo 113-8603, Japan. 2Department of Anesthesiology and Intensive Care Medicine, Kochi Medical School, Kochi, Japan. 3Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Chiba, Japan. 4Department of Acute Medicine, Nihon University School of Medicine, Tokyo, Japan.

Received: 19 May 2020 Accepted: 11 June 2020
Published online: 03 July 2020

References
1. Yokobori S, Yamaguchi M, Igashiri Y, Hironaka K, Onda H, Kuwamoto K, et al. Outcome and refractory factor of intensive treatment for geriatric traumatic brain injury: analysis of 1165 cases registered in the Japan Neurotrauma data Bank. World Neurosurg. 2016;86:127–33.
2. Gustavsson A, Svensson M, Jacobson F, Algilander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–79.
3. Vink R, Nimmo AJ. Multifunctional drugs for head injury. Neurotherapeutics. 2009;6(1):28–42.
4. Ishii K, Kinoshita T, Kiriude G, Watanabe A, Yamakawa K, Nakao S, et al. Impact of initial coagulation and fibrinolytic markers on mortality in patients with severe blunt trauma: a multicentre retrospectvive observational study. Scand J Trauma Resusc Emerg Med. 2019;27(1):25.
5. Hifumi T, Kuroda Y, Kawakita Y, Yamashita S, Oda Y, Doshi K, et al. Therapeutic hypothermia in patients with coagulopathy following severe traumatic brain injury. Scand J Trauma Resusc Emerg Med. 2017;25(1):120.
6. Nakae R, Takayama Y, Kusumoto K, Naoe Y, Sato H, Yokota H. Time course of coagulation and fibrinolytic parameters in patients with traumatic brain injury. J Neurotrauma. 2016;33(7):688–95.
7. Huebner BR, Doflac WC, Cribari C. Tranexamic acid use in prehospital uncontrolled hemorrhage. Wilderness Environ Med. 2017;28(2S):550–60.
8. Roberts I, Shukur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(101):1–79.
9. CRASH collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019; 394(10192):1713–23.
10. CRASH-2 trial collaborators, et al. Lancet. 2010;376(9734):23–32.
11. Roberts I, Shukur H, Ker K, Coats T, CRASH collaborators. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2011;1:CD004896.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care evaluations: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.
13. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
14. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94.
15. Chakroun-Wallah Q, Samet A, Jerbi M, Elbers RG, Blencowe NS, Bouton I, et al. Benefits of the tranexamic acid in head trauma with no extracranial bleeding: a prospective follow-up of 180 patients. Eur J Trauma Emerg Surg. 2019;45(4):719–26.
16. Fakharian E, Abazadeh-Kalhroudi M, Atoof F. Effect of tranexamic acid on prevention of hemorhagic mass growth in patients with traumatic brain injury. World Neurosurg. 2018;109e748–e53.
17. Jokar A, Ahmadi K, Salehi T, Sharif-Ahoseini M, Rahimi-Movaghar V. The effect of tranexamic acid in traumatic brain injury: a randomized, double-blinded, placebo-controlled trial. BMC Emerg Med. 2013;13:20.
18. Yutthakasemsunt S, Kittivatatanagul W, Piyachevpirat P, Thinkamrop B, Phuenpathom N, Lumbiganon P. Tranexamic acid for patients with traumatic brain injury: a randomized, double-blind, placebo-controlled trial. Rev Recent Clin Trials. 2019;14(4):286–91.
19. Elhadi M, Mozafari J, Ilkhchi RB, Hanafi MG, Mousavinejad M. Intravenous tranexamic acid for subdural and epidural intracranial hemorrhage: randomized, double-blind, placebo-controlled trial. J Neurosurg Anesthesiol. 2019;31(5):424–30.
20. Zehtabchi S, Abdel Baki SG, Falzon L, Nishijima DK. Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis. Am J Emerg Med. 2014;32(12):1503–9.
21. Ker K, Roberts I, Shukur H, Coats TJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2015;5:CD004896.
22. Weng S, Wang W, Wei Q, Lan H, Su J, Xu Y. Effect of tranexamic acid in patients with traumatic brain injury: a systematic review and meta-analysis. World Neurosurg. 2019;123:128–35.

23. Cai J, Ribkoff J, Olson S, Raghunathan V, Al-Samkari H, DeLoughery TG, et al. The many roles of tranexamic acid: an overview of the clinical indications for TXA in medical and surgical patients. Eur J Haematol. 2020;104(2):79–87.

24. Woman Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–16.

25. Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Bini SA, Clarke HD, et al. Tranexamic acid use in total joint arthroplasty: the clinical practice guidelines endorsed by the American Association of hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic surgeons, hip society, and knee society. J Arthroplast. 2018;33(10):3065–9.

26. Wada T, Gando S, Maekawa K, Katabami K, Sageshima H, Hayakawa M, et al. Disseminated intravascular coagulation with increased fibrinolysis during the early phase of isolated traumatic brain injury. Crit Care. 2017;21(1):219.

27. World Health Organization. Model List of Essential Medicines 21st, 2019. https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=1. Accessed 1 May 2020.

28. Lin Z, Xiaoyi Z. Tranexamic acid-associated seizures: a meta-analysis. Seizure. 2016;36:70–3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.